Navigation Links
Chimerix Raises $16.1 Million in Series E Financing
Date:8/11/2009

RESEARCH TRIANGLE PARK, N.C., Aug. 11 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, today announced the completion of a $16.1 million Series E financing. Leading life science venture capital investors Canaan Partners, Alta Partners, Sanderling Ventures and Asset Management Company participated in this insider round.

Proceeds from the financing will primarily be used to expand Chimerix's clinical development program for its lead drug candidate, CMX001. CMX001 has shown activity in early clinical studies as a broad-spectrum antiviral drug, and is currently being evaluated for the treatment of cytomegalovirus (CMV) and BK virus in Phase II clinical trials. CMX001 is also being developed as a biodefense agent for the treatment of smallpox and complications associated with smallpox vaccination. In addition, Chimerix expects to advance CMX157, an anti-HIV drug, into Phase I clinical development and to continue work on a library of compounds that have shown extremely potent activity against a range of viral diseases including hepatitis C.

"Chimerix's robust pharmaceutical product pipeline and world-class expertise in the area of antiviral medicines offer truly novel and promising approaches for the treatment of a number of challenging viral and inflammatory diseases," said Seth Rudnick, M.D., of Canaan Partners and Co-Chairman of the company's Board of Directors. "We believe that this financing will enable the Chimerix team to continue doing what they do best - identify, optimize and develop important new antiviral medicines that address significant therapeutic markets and may prove valuable in our nation's biodefense strategy."

"We are pleased by the consistent support Chimerix has received from such a premier group of experienced life science investors," said George Painter, Ph.D., Chimerix's President and Chief Executive Officer. "These funds will enable us to drive forward clinical development of our promising drug candidates to a point where we are well-positioned to make strategic decisions about the best course for late-stage clinical development, as well as potential partnering with leading pharmaceutical companies."

About Chimerix

Chimerix, Inc., discovers, develops and commercializes antiviral therapeutics with enhanced pharmaceutical properties for the treatment of a range of life-threatening diseases. Leveraging a powerful lipid technology, Chimerix is able to develop drug candidates with oral availability or topical applications with increased potency and targeted delivery. These enhanced pharmaceutical properties can be applied to new drug moieties or known drugs to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse events. The company's lead compound, CMX001, has shown promise as a broad-spectrum antiviral drug and is currently being developed as a biodefense agent for the treatment of smallpox and complications associated with smallpox vaccination, as well as for the treatment of infections that cause morbidity and mortality in immunocompromised patients such as cytomegalovirus (CMV) and BK virus. Chimerix's pipeline includes an anti-HIV drug, CMX157, in late-stage preclinical studies. Chimerix is also advancing programs in hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. For further information, please visit the company's website athttp://www.chimerix-inc.com/.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ex-House Aging Committee Chief of Staff Bob Weiner Warns of Insurance Control Over Health Bill Outcome, Praises House Version, Disappointed by Senate; Weiner and Policy Analyst Jordan Osserman Offer Bills Prognosis
2. High cholesterol in midlife raises risk of late-life dementia, Kaiser Permanente study finds
3. High Cholesterol in Midlife Raises Risk of Late-Life Dementia, Kaiser Permanente Study Finds
4. HMS Holdings Corp. Announces Q2 2009 Results and Raises 2009 Guidance
5. Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook
6. Be a Hero For Babies Day Raises $2.6 Million for March of Dimes
7. Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance
8. Universal Health Services, Inc. Reports Significant Increases In 2009 Second Quarter and Six-Month Earnings, Raises Full Year Guidance
9. aTyr Pharma Raises an Additional $12 Million
10. Applied Physiology Raises $5 Million for Navigator™ Market Launch
11. Wyeth Reports Earnings Results for the 2009 Second Quarter and First Half and Raises Full Year 2009 Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... ... 2017 , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals made exclusively ... any logo with a glitch reveal in just a few clicks of a mouse. Customizable ... of each preset. Use these presets to add a uniquely animated logo to any photos ...
(Date:2/18/2017)... VA (PRWEB) , ... February ... ... of Change for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March ... , Are manufacturers looking to reduce their regulatory burden? Pay dividends in ...
(Date:2/18/2017)... ... 17, 2017 , ... CONTACT:, Glenn Vallecillos, MD, FACS, +1 ... Dr. Glenn Vallecillos experiments SculpSure, the hot, new, aesthetic, non-surgical procedure ... been centered around that idea that to achieve ones desired results a surgical ...
(Date:2/18/2017)... , ... February 18, 2017 , ... ... provides the latest information and contact points to easily connect elderly veterans of ... assisted living, and elder-care funding. It also conveys material on this year's increase ...
(Date:2/17/2017)... San Diego, CA (PRWEB) , ... February 17, ... ... new initiative—InvestUp—to focus on foundational and sustainable systems change designed to further positively ... Counties. , “The Board of Trustees has long considered it our duty to ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... South Africa , Feb. 20, 2017  There ... illness and non-communicable diseases (NCDs) across sub-Saharan Africa, which ... drugs. The growing incidence of more Western lifestyle diseases ... disease, in addition to infectious and parasitic illness, will ... with a business opportunity of $40.8 billion in ...
(Date:2/20/2017)... According to a new market research report "Pulmonary/ Respiratory Drug ... dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications ... to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in ... Continue Reading ... ...
(Date:2/20/2017)... --  Alberty   Drugs , a leading ... has announced a significant shift in focus by concentrating ... servicing local Veteran Affairs Centers (VA) and other Federal ... need to secure cost effective treatments for their patients, ... their goods & services. "The opportunity to ...
Breaking Medicine Technology: